Alto Neuroscience (NYSE:ANRO) Earns "Outperform" Rating from William Blair
Alto Neuroscience (NYSE:ANRO) has received an "outperform" rating from William Blair. Several other equity analysts have also given positive ratings on the company. The stock is currently trading at $13.84, with a 50-day simple moving average of $14.58. CFO Nicholas Conrad Smith recently purchased 6,150 shares of Alto Neuroscience stock. Institutional investors, including Price T Rowe Associates and Vanguard Group, have also shown interest in the company. Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing treatments for major depressive disorder and post-traumatic stress disorder.
Alto Neuroscience (NYSE:ANRO - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at William Blair in a research note issued to investors on Wednesday, RTT News reports.
Get Alto Neuroscience alerts:
Several other equities analysts also recently commented on the company. Jefferies Financial Group assumed coverage on Alto Neuroscience in a research report on Tuesday, February 27th. They issued a "buy" rating and a $33.00 target price on the stock. Stifel Nicolaus reissued a "buy" rating and set a $32.00 target price on shares of Alto Neuroscience in a report on Monday, March 25th. TD Cowen assumed coverage on shares of Alto Neuroscience in a research note on Tuesday, February 27th. They issued an "outperform" rating on the stock. Finally, Robert W. Baird assumed coverage on shares of Alto Neuroscience in a research note on Tuesday, February 27th. They issued an "outperform" rating and a $32.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $32.33.
Check Out Our Latest Report on ANRO
Alto Neuroscience Stock Performance
NYSE:ANRO traded down $0.32 during mid-day trading on Wednesday, hitting $13.84. The stock had a trading volume of 121,223 shares, compared to its average volume of 204,141. Alto Neuroscience has a twelve month low of $12.78 and a twelve month high of $24.00. The stock has a 50 day simple moving average of $14.58.
Insider Buying and Selling at Alto Neuroscience
In other Alto Neuroscience news, CFO Nicholas Conrad Smith purchased 6,150 shares of the company's stock in a transaction dated Thursday, March 28th. The stock was purchased at an average price of $16.36 per share, for a total transaction of $100,614.00. Following the transaction, the chief financial officer now owns 26,866 shares in the company, valued at approximately $439,527.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Institutional Investors Weigh In On Alto Neuroscience
A number of institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD purchased a new position in Alto Neuroscience in the first quarter worth $9,788,000. Vanguard Group Inc. acquired a new stake in shares of Alto Neuroscience in the first quarter worth approximately $8,233,000. Jennison Associates LLC acquired a new stake in Alto Neuroscience in the 1st quarter valued at about $7,039,000. Finally, University of Texas Texas AM Investment Managment Co. acquired a new position in Alto Neuroscience in the first quarter valued at approximately $340,000.
About Alto Neuroscience
(Get Free Report)Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Featured Stories
- Five stocks we like better than Alto Neuroscience
- What is the Australian Securities Exchange (ASX)
- How to Buy the Dip and Sell the Rip on Your Stocks with Options
- Market Cap Calculator: How to Calculate Market Cap
- 3 Hot Buyback Plans Supporting Price Action in 2024
- How to Read Stock Charts for Beginners
- Stocks With Subscription Based Revenue Offer Inflation Protection
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ This is the best new way to score with AI (From Weiss Ratings) (Ad)
Should you invest $1,000 in Alto Neuroscience right now?
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
